StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Qulipta (atogepant) — U.S. reported growth YoY by Quarter

Qulipta (atogepant) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Qulipta (atogepant) — U.S. reported growth YoY: 22.1% in Q2 2026, down 40.7 pts from a year earlier. That is the lowest of the 10 quarters on record here.

Latest, Q2 2026
22.1%
Period ended Jun 30, 2026
Change on a year earlier
-40.7 pts
62.8% in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Qulipta | 289 | 61 | 350 | 22.1”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedQulipta (atogepant) — U.S. reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202622.1%-40.7 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202645.4%+11.2 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202530.9%-34.8 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202550.2%+21.9 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202562.8%+10.0 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202534.2%-60.3 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202465.7%–Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202428.3%–Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202452.8%–Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202494.5%–Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗

Cite this data

StockData. (2026). AbbVie Qulipta (atogepant) — U.S. reported growth YoY (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/qulipta-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.